U.S. markets closed

Exact Sciences Corporation (EXAS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
150.00+1.93 (+1.30%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close148.07
Open146.84
Bid150.00 x 2200
Ask151.20 x 800
Day's Range146.22 - 150.32
52 Week Range35.25 - 152.87
Volume1,370,068
Avg. Volume1,999,838
Market Cap25.312B
Beta (5Y Monthly)1.65
PE Ratio (TTM)N/A
EPS (TTM)-2.27
Earnings DateFeb 09, 2021 - Feb 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est154.79
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • 15 Best Undervalued Stocks to Buy Now
    Insider Monkey

    15 Best Undervalued Stocks to Buy Now

    In this article, we present to you the 15 Best Undervalued Stocks to Buy Now. If you’re in a hurry, click to skip ahead and jump to the 5 Best Undervalued Stocks to Buy Now. Investing in the stock market could be difficult. We can classify investors based on their portfolios. The low risk-takers who […]

  • Exact Sciences (EXAS) Posts Solid Preliminary Q4 Testing Revenues
    Zacks

    Exact Sciences (EXAS) Posts Solid Preliminary Q4 Testing Revenues

    Exact Sciences' (EXAS) strength in Screening revenue along with a robust COVID-19 testing arm are likely to have boosted the top line significantly.

  • Exact Sciences Licenses Targeted Digital Sequencing Method to Extend Leadership in Precision Oncology
    PR Newswire

    Exact Sciences Licenses Targeted Digital Sequencing Method to Extend Leadership in Precision Oncology

    Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has acquired a worldwide exclusive license to the proprietary TARDIS technology from The Translational Genomics Research Institute (TGen), an affiliate of City of Hope. This compelling and technically distinct approach will help expand Exact Sciences' leadership in precision oncology and offers a differentiated patient-specific solution in minimal residual disease testing.